ADCT: Nakamit ng LOTIS-5 Phase 3 topline ang endpoint ng PFS para sa ZYNLONTA + rituximab

Natugunan ng Phase 3 LOTIS-5 trial ang pangunahing endpoint ng PFS nito na may istatistikang kahalagahan (HR 0.73, p=0.008). Plano ng ADC Therapeutics ang isang pre-sBLA meeting sa FDA sa Agosto 2026 at isang pagsusumite ng sBLA sa Q4 2026 upang humingi ng buong pag-apruba para sa ZYNLONTA kasama ang rituximab sa r/r DLBCL.

Mahahalagang fact

Na-file: Hun 3, 2026, 08:17 PM
Kaganapan: Topline na resulta
Direksyon: Positibo
Kumpanya: ADCTADC Therapeutics
Asset: loncastuximab tesirine-lpyl
Pinagmulan: SEC 8-K
Kumpiyansa: May source
HR: 0.73
CR rate: 39.5% vs 26.7%
p-value: 0.008
median PFS: 6.1 vs 4.7 months
median docr: 16.8 vs 12.3 months

Sipi mula sa source

false 0001771910 0001771910 2026-06-03 2026-06-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 3, 2026 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Number) N/A (IRS Employer Identification Number) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of Principal Executive Offices) (Zip Code) + 41 21 653 02 00 (Registrant’s Telephone Number) N/A (Former Name or Former Address, if Changed Since Last Report) Ch

SEC 8-K